About aethlon medical - AEMD
Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. It develops Aethlon Hemopurifier, which is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The firm operates through the following segments: Aethlon and ESI. The Aethlon segment is involved in therapeutic business activities. The ESI segment consists of diagnostic business activities. The company was founded by James A. Joyce on April 17, 1991 and is headquartered in San Diego, CA.
AEMD At a Glance
Aethlon Medical, Inc.
11555 Sorrento Valley Road
San Diego, California 92121
| Phone | 1-619-941-0360 | Revenue | 0.00 | |
| Industry | Medical Specialties | Net Income | -7,151,469.00 | |
| Sector | Health Technology | Employees | 9 | |
| Fiscal Year-end | 03 / 2027 | |||
| View SEC Filings |
AEMD Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.704 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.436 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.17 |
AEMD Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -794,607.667 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
AEMD Liquidity
| Current Ratio | 3.704 |
| Quick Ratio | 3.704 |
| Cash Ratio | 3.474 |
AEMD Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -104.457 |
| Return on Equity | -142.889 |
| Return on Total Capital | -132.408 |
| Return on Invested Capital | -138.239 |
AEMD Capital Structure
| Total Debt to Total Equity | 10.536 |
| Total Debt to Total Capital | 9.532 |
| Total Debt to Total Assets | 8.129 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |